Cannabidiol Found to Reduce Seizure Frequency in New Trail

Cannabidiol (CBD) Found to Reduce Seizure Frequency in Phase III Trial

The oral administration of CBD (cannabidiol) reduces seizure frequency in children with intractable epilepsy, according to placebo-controlled, randomized trial data published in The New England Journal of Medicine. In this double-blind, placebo-controlled trial, they randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day or placebo, in addition to standard antiepileptic treatment. The primary end point was the change in convulsive-seizure frequency over a 14-week treatment period, as compared with a 4-week baseline period.

A team of investigators from the United States and England evaluated the effects of pharmaceutically standardized cannabidiol extracts (aka Epidiolex) versus placebo in 120 children and young adults with treatment-resistant Dravet syndrome.

They reported:

“The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo.”

Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo.


Leave a Reply

Your email address will not be published. Required fields are marked *